drugset / Trial / NCT05265325
A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a phase II study to evaluate the safety and efficacy of AND017 in renal anemia patients on dialysis
Timeline
- Start
- 2023-05-03
- Primary completion
- 2024-02-29
- Completion
- 2024-04-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AND017 | Unknown | 2 mg | Oral |
| Subject | AND017 | Unknown | 4 mg | Oral |
| Subject | AND017 | Unknown | 8 mg | Oral |
| Comparator | Darbepoetin alfa | Protein / enzyme biologic | — | — |
| Comparator | epoetin alfa | Protein / enzyme biologic | — | — |
| Comparator | methoxy polyethylene glycol-epoetin beta | Protein / enzyme biologic | — | — |